- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
- 10-K Annual report
- 3.3 Amended and Restated By-laws
- 4.1 Amended and Restated Rights Agreement, Dated As of February 27, 2009
- 10.29 Development and Commercialization Agreement Dated As of January 4, 2009
- 10.30 Securities Purchase Agreement Dated As of January 4, 2009
- 10.31 Amd. No. 1 to the Development and Commercialization Agreement
- 10.32 Amd. No. 1 to the Securities Purchase Agreement
- 10.33 Summary of Bonus Plan
- 21.1 Subsidiaries of Biomarin Pharmaceutical Inc.
- 23.1 Consent of KPMG LLP, Independent Registered Public Accounting Firm
- 23.2 Consent of Pricewaterhousecoopers, LLP
- 31.1 Certification of Chief Executive Officer
- 31.2 Certification of Chief Financial Officer
- 32.1 Certification of Chief Executive Officer and Chief Financial Officer
- 99.1 Biomarin/genzyme LLC Consolidated Financial Statements
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors and Stockholders
BioMarin Pharmaceutical Inc.:
We consent to the incorporation by reference in (i) the registration statements (Nos. 333-136963, 333-84787, and 333-85368) on Form S-8 and (ii) the registration statement (No. 333-132566) on Form S-3 of BioMarin Pharmaceutical Inc. and subsidiaries of our reports dated February 24, 2009, with respect to the consolidated balance sheets of BioMarin Pharmaceutical Inc. and subsidiaries as of December 31, 2008 and 2007, and the related consolidated statements of operations, stockholders’ equity (deficit) and comprehensive income (loss), and cash flows for each of the years in the three-year period ended December 31, 2008, and the effectiveness of internal control over financial reporting as of December 31, 2008, which reports appear in the December 31, 2008 annual report on Form 10-K of BioMarin Pharmaceutical Inc.
Our reports were based on our audits and the report of other auditors.
(Signed) KPMG LLP
San Francisco, California
February 24, 2009